383181-52-0

Upstream product

• 383181-51-9 3,5-dibromo-4-(4-nitrophenoxy) phenol 
• 105-36-2 ethyl bromoacetate 
• 383181-48-4 1,3-dibromo-5-fluoro-2-(4-nitrophenoxy)benzene 
• 383181-49-5 1,3-dibromo-5-methoxy-2-(4-nitrophenoxy)benzene 

Downstream Products

• 383181-53-1 ethyl [4-(4-aminophenoxy)-3,5-dibromophenoxy]acetate 
• 918946-12-0 methyl [4-(4-aminophenoxy)-3,5-dibromophenoxy]acetate 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS AGONISTS FOR THE THYROID RECEPTOR

The invention provides Compounds of formula (I) or pharmaceutically acceptable esters, amides, solvates or salts thereof, including salts of such esters or amides, and solvates of such esters, amides or salts, wherein R3, R4, G, Y, W and R5 are as defined in the specification. The invention also provides the use of such Compounds in the treatment or Prophylaxis of a condition associated with a disease or disorder associated with thyroid receptor activity.

NOVEL PHARMACEUTICAL COMPOSITIONS

The invention provides the use of compounds of formula (I) or pharmaceutically acceptable esters, amides, solvates or salts thereof, including salts of such esters or amides, and solvates of such esters, amides or salts, for the manufacture of a medicament for the treatment or prophylaxis of a condition that may be treated with a thyroid receptor agonist or partial agonist wherein R1, R2, R3, R4, Y, W and R5 are as defined in the specification. The invention also provides compounds of formula (Ia) or pharmaceutically acceptable esters, amides, solvates or salts thereof, including salts of such esters or amides, and solvates of such esters, amides or salts, formula (Ia) wherein R1, R2, R3, R4, Y, W and R5 are as defined in the specification.

INDOLE DERIVATIVES AND THEIR USE AS THYROID RECEPTOR LIGANDS

The invention provides compounds of formula (I) or pharmaceutically acceptable esters, amides, solvates or salts thereof, including salts of such esters or amides, and solvates of such esters, amides or salts, (I) wherein R1, R2, R3, R4, R5, R6, Y and W are as defined in the specification. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition that may be treated with a thyroid receptor agonist or partial agonist.